Revealed: 1 Marijuana Stock I Like More Than Aurora Cannabis (TSX:ACB)

Fire & Flower Holdings Inc. (TSXV:FAF) is one cannabis penny stock that could make you filthy rich.

| More on:

In prior pieces, I’ve highlighted several reasons why Aurora Cannabis was one of my preferred picks in the highly speculative marijuana market. Aurora was growing tonnes of weed in a somewhat efficient manner, which is how a firm can succeed in a commoditized market.

Although you could make a quick buck from betting on cannabis cultivators, I’d much prefer owning shares of a company that’s able to differentiate itself in some form or another. As a grower and distributor of weed, there isn’t much wiggle room to promote brand differentiation with all the regulations that are in place.

Aurora Cannabis and many other pot firms have hovered in the grey area in the past with the hopes of making a name for themselves through the promotion of music festivals. As Health Canada cracks down on the rule breakers, however, every firm’s compliance will be heightened, making it nearly impossible to garner brand loyalty.

How can a cannabis company differentiate itself with all that red tape?

It’s simple: don’t be a cannabis producer, and you won’t be subject to the regulations that seek to make product differentiation next to impossible.

Fire & Flower Holdings (TSXV:FAF), an Edmonton-based cannabis retailer, recently caught my attention after Alimentation Couche-Tard announced its 9.9% stake in the company with the option to own a controlling stake in the firm should it choose to.

Fire & Flower is a marijuana penny stock with a market cap of just $160 million. Shares trade for $1.35, and although I’ve urged Foolish investors to avoid penny stocks like the plague, I think Fire & Flower is a rare exception. It’s a legitimate play that likely has a risk/reward trade-off that favours the investor.

The cannabis retailer has only 23 cannabis shops across the prairies and Ontario. Although it’s tough to trust the management team of a firm that’s as small as Fire & Flower, I am encouraged by all the good things that CEO Brian Hannasch had to say about the management and its expertise in physical and digital cannabis retail.

Moreover, one can’t help but notice how gorgeous the Fire & Flower store layout is. It’s like the Apple store of weed. And although such an arrangement can easily be replicated by some other micro-cap up-and-comer, I think Fire & Flower can keep competitors at bay thanks to the involvement of Couche-Tard and its deep pockets, which will help the company scale up faster than its less-capitalized peers.

Couche-Tard has a brilliant management team that’s been delivering market-crushing results for investors over the years. They’re prudent when it comes to M&A, and it’s going to be no different with Couche-Tard’s initial investment in the world of cannabis.

Hannasch and company clearly see something in Fire & Flower, and it’s not hard to see why. The company has a robust online presence and ample room for an ambitious national expansion. Although Couche-Tard’s initial investment is just a toe in the waters, I think Fire & Flower may be scooped up entirely in a few years’ time should things go smoothly.

In any case, Fire & Flower is a sound investment — not a speculation, despite being in deep penny-stock territory.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette owns shares of ALIMENTATION COUCHE-TARD INC and Apple. David Gardner owns shares of Apple. The Motley Fool owns shares of Apple and has the following options: short January 2020 $155 calls on Apple, long January 2020 $150 calls on Apple, short January 2020 $155 calls on Apple, and long January 2020 $150 calls on Apple. Couche-Tard is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

1 Cannabis Stock That’s My Speculative Sector Play

The cannabis boom has come and gone, but this cannabis stock may still have a chance to rise higher.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold in July 2025?

Read this if you're still bagholding Canopy Growth in 2025.

Read more »

Stethoscope with dollar shaped cord
Cannabis Stocks

Best Stock to Buy Right Now: Bausch Health vs Canopy Growth?

While both stocks are risky, Bausch Health is seeing operational momentum, while Canopy Growth is still struggling with losses.

Read more »

Worker checks cannabis flower in lab farm greenhouse
Cannabis Stocks

Down an Incredible 99% From All-Time Highs, Is Canopy Growth Stock Worth Buying Now?

Canopy Growth stock remains a high-risk investment in 2025 due to its weak balance sheet and volatile profit margins.

Read more »

money goes up and down in balance
Dividend Stocks

2 Incredibly Cheap Growth Stocks to Buy Now

These two growth stocks are both unbelievably cheap and have significant long-term potential, making them some of the best to…

Read more »

A cannabis plant grows.
Stocks for Beginners

1 Canadian Cannabis Stock Down 57% to Buy Now for Future Growth

Cannabis stocks might seem so 2018, but this one could eventually make a major comeback.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »